4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run

Core Insights - The MedTech sector is experiencing growth driven by the adoption of AI and robotic-assisted surgeries, despite facing challenges from labor shortages and geopolitical issues [1][4] - Innovations in digital health, AI, and personalized medicine are expected to provide significant growth prospects for the MedTech sector in 2025 [2] - The sector is characterized by defensive qualities, making it resilient against inflationary pressures and market volatility [2][5] Industry Overview - In 2024, the MedTech sector faced significant challenges due to geopolitical tensions, healthcare labor shortages, and inflationary pressures, yet it remained more stable compared to other sectors [1][4] - The global AI in healthcare market is projected to grow from $26.69 billion in 2024 to $613.81 billion by 2034, with a CAGR of approximately 36.8% [6] - The Federal Reserve's rate cuts and favorable monetary policies are expected to improve borrowing conditions, further supporting the MedTech sector [5] Company Highlights - Doximity, Inc. (DOCS): Reported strong fiscal 2025 results with a projected 20% improvement in earnings per share. The stock has gained 107.1% over the past year [9][10] - Clover Health Investments, Corp. (CLOV): Announced solid revenue growth and a 41.7% improvement in projected loss per share for 2025. The stock has gained 223% over the past year [11][13] - ClearPoint Neuro, Inc. (CLPT): Reported increased revenues and received FDA marketing authorization for a new product. The stock has gained 136.9% over the past year [14][16] - Hims & Hers Health, Inc. (HIMS): Showed strong revenue growth and a projected 40.9% improvement in revenues for 2025. The stock has gained 205% over the past year [17][19]